Adam Scott Levy Sells 12,946 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 12,946 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $14.04, for a total transaction of $181,761.84. Following the sale, the chief financial officer owned 193,666 shares in the company, valued at $2,719,070.64. This represents a 6.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Adam Scott Levy also recently made the following trade(s):

• On Wednesday, July 30th, Adam Scott Levy sold 59,925 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.76, for a total transaction of $884,493.00.
• On Tuesday, July 29th, Adam Scott Levy sold 807 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.00, for a total transaction of $11,298.00.
• On Friday, July 11th, Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.45, for a total transaction of $155,453.10.

Mineralys Therapeutics Price Performance

Shares of Mineralys Therapeutics stock opened at $13.66 on Friday. The company’s 50 day moving average price is $14.52 and its two-hundred day moving average price is $13.27. The firm has a market capitalization of $890.36 million, a P/E ratio of -3.66 and a beta of -0.29. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.23. On average, analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Hedge Funds Weigh In On Mineralys Therapeutics

Several large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock valued at $271,000 after acquiring an additional 702 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Mineralys Therapeutics by 4.6% during the first quarter. AlphaQuest LLC now owns 15,925 shares of the company’s stock valued at $253,000 after acquiring an additional 703 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock worth $34,000 after buying an additional 850 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in Mineralys Therapeutics by 297.5% during the first quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company’s stock worth $25,000 after buying an additional 1,190 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Mineralys Therapeutics by 0.7% during the fourth quarter. Northern Trust Corp now owns 246,113 shares of the company’s stock worth $3,030,000 after buying an additional 1,688 shares during the last quarter. Institutional investors own 84.46% of the company’s stock.

Analyst Ratings Changes

MLYS has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday, June 17th. Jefferies Financial Group initiated coverage on shares of Mineralys Therapeutics in a research report on Tuesday, June 10th. They issued a “hold” rating and a $15.00 target price on the stock. Wall Street Zen lowered shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Finally, Guggenheim set a $48.00 target price on shares of Mineralys Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $32.25.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.